Plain-English translation of NCT07271121 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment called MB-CART19.1, which is made from your own immune cells that have been engineered in a lab to recognize and fight lymphoma cells. You would receive one infusion of these cells through an IV. The trial is studying whether this medication is safe and effective for patients whose lymphoma has come back or stopped responding to previous treatments.
Patients with lymphoma that has relapsed or become resistant to standard chemotherapy have very limited options and poor outcomes. This trial exists to see whether engineering your own immune cells to target the cancer could offer a new and potentially more effective treatment path for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You will undergo a procedure called leukapheresis, where blood is drawn to collect your immune cells, which are then sent to a lab to be engineered. Once the cells are ready, you will return for a single infusion that takes about 5–20 minutes and is given through an IV. After that, you will have regular follow-up visits and blood tests to monitor how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Jordan